These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 38549502)

  • 1. Flexible seamless 2-in-1 design with sample size adaptation.
    Li R; Wu L; Liu R; Lin J
    J Biopharm Stat; 2024 Mar; ():1-19. PubMed ID: 38549502
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A seamless phase II/III design with dose optimization for oncology drug development.
    Li Y; Zhang Y; Mi G; Lin J
    Stat Med; 2024 Aug; 43(18):3383-3402. PubMed ID: 38845095
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adaptive design implementation in confirmatory trials: methods, practical considerations and case studies.
    Li Q; Lin J; Lin Y
    Contemp Clin Trials; 2020 Nov; 98():106096. PubMed ID: 32739496
    [TBL] [Abstract][Full Text] [Related]  

  • 4. An adaptive seamless Phase 2-3 design with multiple endpoints.
    Jin M; Zhang P
    Stat Methods Med Res; 2021 Apr; 30(4):1143-1151. PubMed ID: 33588655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Seamless phase 2/3 oncology trial design with flexible sample size determination.
    Teng Z; Tian Y; Liu Y; Liu G
    Stat Med; 2020 Aug; 39(18):2373-2386. PubMed ID: 32338410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptive two-stage seamless sequential design for clinical trials.
    Gao P; Li Y
    J Biopharm Stat; 2024 May; ():1-23. PubMed ID: 38704845
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adaptive Design: A Review of the Technical, Statistical, and Regulatory Aspects of Implementation in a Clinical Trial.
    Cerqueira FP; Jesus AMC; Cotrim MD
    Ther Innov Regul Sci; 2020 Jan; 54(1):246-258. PubMed ID: 32008232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bayesian predictive power for interim adaptation in seamless phase II/III trials where the endpoint is survival up to some specified timepoint.
    Schmidli H; Bretz F; Racine-Poon A
    Stat Med; 2007 Nov; 26(27):4925-38. PubMed ID: 17590875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using surrogate information to improve confirmatory platform trial with sample size re-estimation.
    Zhong C; Li Q; Wu L; Lin J
    J Biopharm Stat; 2022 Jul; 32(4):547-566. PubMed ID: 35714331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Seamless phase 2/3 design for trials with multiple co-primary endpoints using Bayesian predictive power.
    Yang J; Li G; Yang D; Wu J; Wang J; Gao X; Liu P
    BMC Med Res Methodol; 2024 Jan; 24(1):12. PubMed ID: 38233758
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sample size adjustment based on promising interim results and its application in confirmatory clinical trials.
    Chen YH; Li C; Lan KK
    Clin Trials; 2015 Dec; 12(6):584-95. PubMed ID: 26195615
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adaptive clinical trial designs with pre-specified rules for modifying the sample size: understanding efficient types of adaptation.
    Levin GP; Emerson SC; Emerson SS
    Stat Med; 2013 Apr; 32(8):1259-75; discussion 1280-2. PubMed ID: 23081665
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proposed study designs for approval based on a surrogate endpoint and a post-marketing confirmatory study under FDA's accelerated approval regulations for disease modifying osteoarthritis drugs.
    Kraus VB; Simon LS; Katz JN; Neogi T; Hunter D; Guermazi A; Karsdal MA
    Osteoarthritis Cartilage; 2019 Apr; 27(4):571-579. PubMed ID: 30465809
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An adaptive seamless 2-in-1 design with biomarker-driven subgroup enrichment.
    Wu L; Lin J
    J Biopharm Stat; 2024 Apr; ():1-15. PubMed ID: 38651758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
    Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
    Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving interim decisions in randomized trials by exploiting information on short-term endpoints and prognostic baseline covariates.
    Van Lancker K; Vandebosch A; Vansteelandt S
    Pharm Stat; 2020 Sep; 19(5):583-601. PubMed ID: 32248662
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Testing multiple primary endpoints in clinical trials with sample size adaptation.
    Liu Y; Hu M
    Pharm Stat; 2016; 15(1):37-45. PubMed ID: 26607410
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Statistical tests for two-stage adaptive seamless design using short- and long-term binary outcomes.
    Takahashi K; Ishii R; Maruo K; Gosho M
    Stat Med; 2022 Sep; 41(21):4130-4142. PubMed ID: 35713225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of group sequential, information-based sample size re-estimation in the design of the PRIMO study of chronic kidney disease.
    Pritchett Y; Jemiai Y; Chang Y; Bhan I; Agarwal R; Zoccali C; Wanner C; Lloyd-Jones D; Cannata-Andía JB; Thompson T; Appelbaum E; Audhya P; Andress D; Zhang W; Solomon S; Manning WJ; Thadhani R
    Clin Trials; 2011 Apr; 8(2):165-74. PubMed ID: 21478328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.